-
Start Preamble
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 8, 2009, Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:
Drug Schedule Dihydromorphine (9145) I Amphetamine (1100) II Methamphetamine (1105) II Amobarbital (2125) II Pentobarbital (2270) II Secobarbital (2315) II Phenylacetone (8501) II Cocaine (9041) II Codeine (9050) II Dihydrocodeine (9120) II Oxycodone (9143) II Hydromorphone (9150) II Diphenoxylate (9170) II Ecgonine (9180) II Hydrocodone (9193) II Meperidine (9230) II Methadone (9250) II Morphine (9300) II Oxymorphone (9652) II Alfentanil (9737) II Remifentanil (9739) II Sufentanil (9740) II Fentanyl (9801) II The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.
Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 9, 2009.
Start SignatureStart Printed Page 46232End Signature End PreambleDated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E9-21522 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 09/08/2009
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- E9-21522
- Pages:
- 46231-46232 (2 pages)
- PDF File:
- e9-21522.pdf